Literature DB >> 17911646

OX40 controls functionally different T cell subsets and their resistance to depletion therapy.

Alexander Kroemer1, Xiang Xiao, Minh Diem Vu, Wenda Gao, Keisuke Minamimura, Ming Chen, Takashi Maki, Xian Chang Li.   

Abstract

T cell depletion is a widely used approach in clinical transplantation. However, not all T cells are equally sensitive to depletion therapies and a significant fraction of T cells persists even after aggressive treatment. The functional attributes of such T cells and the mechanisms responsible for their resistance to depletion are poorly studied. In the present study, we showed that CD4(+) T cells that are resistant to polyclonal anti-lymphocyte serum (ALS) mediated depletion exhibit phenotypic features of memory cells and uniformly express OX40 on the cell surface. Studies using the foxp3gfp knockin mice revealed that the remaining CD4(+)OX40(+) cells consist of Foxp3(+) Tregs and Foxp3(-) T effector/memory cells. The ALS-resistant CD4(+)OX40(+) cells failed to mediate skin allograft rejection upon adoptive transferring into congenic Rag(-/-) mice, but removal of Foxp3(+) Tregs from the OX40(+) cells resulted in prompt skin allograft rejection. Importantly, OX40 is critical to survival of both Foxp3(+) Tregs and T effector/memory cells. However, OX40 exhibits opposing effects on the functional status of Foxp3(+) Tregs and T effector/memory cells, as stimulation of OX40 on T effector cells induced amplified cell proliferation but stimulation of OX40 on the Foxp3(+) Tregs impaired their suppressor functions. Our study demonstrates that OX40 is a critical molecule in regulating survival and functions of depletion-resistant T cells; and these findings may have important clinical implications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911646     DOI: 10.4049/jimmunol.179.8.5584

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

2.  Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.

Authors:  Damien Bresson; Georgia Fousteri; Yulia Manenkova; Michael Croft; Matthias von Herrath
Journal:  J Autoimmun       Date:  2011-11-06       Impact factor: 7.094

Review 3.  Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells.

Authors:  Hélène Bour-Jordan; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 4.  Recent progress and new perspectives in studying T cell responses to allografts.

Authors:  A Valujskikh; W M Baldwin; R L Fairchild
Journal:  Am J Transplant       Date:  2010-03-26       Impact factor: 8.086

5.  Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.

Authors:  Kui S Voo; Laura Bover; Megan L Harline; Long T Vien; Valeria Facchinetti; Kazuhiko Arima; Larry W Kwak; Yong J Liu
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

6.  Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction.

Authors:  Yun Song; Emilio Margolles-Clark; Allison Bayer; Peter Buchwald
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

Review 7.  Novel Targets for the Treatment of Melanoma.

Authors:  Lara Ambrosi; Shaheer Khan; Richard D Carvajal; Jessica Yang
Journal:  Curr Oncol Rep       Date:  2019-11-06       Impact factor: 5.075

Review 8.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

9.  Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer.

Authors:  Eleonora Timperi; Ilenia Pacella; Valeria Schinzari; Chiara Focaccetti; Luca Sacco; Francesco Farelli; Roberto Caronna; Gabriella Del Bene; Flavia Longo; Antonio Ciardi; Sergio Morelli; Anna Rita Vestri; Piero Chirletti; Vincenzo Barnaba; Silvia Piconese
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

10.  Pretransplant antithymocyte globulin has increased efficacy in controlling donor-reactive memory T cells in mice.

Authors:  K Ayasoufi; H Yu; R Fan; X Wang; J Williams; A Valujskikh
Journal:  Am J Transplant       Date:  2013-01-17       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.